Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center
Clinical Parkinsonism & Related Disorders · 2026 · 15 · 100492
DOI: 10.1016/j.prdoa.2026.100492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2026. Verfasst von Saar Anis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research, American Parkinson's Disease Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Förderung
- Michael J. Fox Foundation for Parkinson's Research
- American Parkinson's Disease Foundation
Zitieren
APA
Anis, S., & Shaffer, S. (2026). Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center. Clinical Parkinsonism & Related Disorders, 15, 100492. https://doi.org/10.1016/j.prdoa.2026.100492
Vancouver
Anis S, Shaffer S. Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center. Clinical Parkinsonism & Related Disorders. 2026;15:100492. doi:10.1016/j.prdoa.2026.100492
BibTeX
@article{Anis2026,
author = {Anis, Saar and Shaffer, Shannon},
title = {Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center},
journal = {Clinical Parkinsonism & Related Disorders},
year = {2026},
volume = {15},
pages = {100492},
doi = {10.1016/j.prdoa.2026.100492}
}
EUVIMED